04:06 AM EDT, 09/24/2024 (MT Newswires) -- Biogen (BIIB) and its collaboration partner UCB said Tuesday that a phase 3 trial of dapirolizumab pegol, intended for the treatment of patients with moderate-to-severe systemic lupus erythematosus, met its primary endpoint.

The study demonstrated clinical improvement in moderate-to-severe disease activity and showed a drug safety profile, consistent with prior studies, the companies said.

Biogen and UCB plan to start a second phase 3 trial of the drug candidate this year.

Systemic lupus erythematosus is a chronic, multifactorial autoimmune disease that can affect multiple organ systems.

Price: 196.00, Change: +0.19, Percent Change: +0.10